ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION

GHENT, Belgium, 23 April 2014 - Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 85,098 common shares have been issued by the Company in exchange for €451,598.59 as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 49,083,327 shares outstanding.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies^®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t:   [phone]
m: [phone] /
     [phone]
e:  [e-mail]

Marieke Vermeersch
Associate Director Investor Relations
t:   [phone]
m: [phone]
e:  [e-mail]
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t:   [phone]
e:  [e-mail]

pdf version of the press release

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1779285